Masterclass series
Live and interactive
Programme 4 – Anticoagulation
Part 1: Optimal anticoagulation reviews in primary care
Plus
Part 2: Optimising anticoagulation outcomes: Right medicine, right patient, right time, right dose, right route
Part 2 has been organised and funded by BMS/Pfizer and is intended for UK Healthcare Professionals only.
The Agenda
How can outcomes be improved in our patients?
| 19:00 – 20:00 | Part 1 – Optimal anticoagulation reviews in primary care Dr Yassir Javaid Introduction from Dr Javaid followed by a reverse case study presentation and discussion with audience participation. |
| 20:00 – 20:45 | Part 2 – Optimising anticoagulation outcomes: Right medicine, right patient, right time, right dose, right route
Part 2 has been organised and funded by BMS/Pfizer and is intended for UK Healthcare Professionals only. Dr Yassir Javaid |
 |
|
17th May 2022, 19:00 hours
Part 1 – Interactive masterclass session
Optimal anticoagulation reviews in primary care
With the increasing number of patients being prescribed direct oral anticoagulants (DOACs), and the patients who remain on warfarin becoming more complex, there appears to be a current lack of a standardised anticoagulation review for patients in primary care, resulting in potentially preventable harm events.
This webinar will offer case-based guidance around what should be considered when reviewing patients in primary care with the ultimate aim of better optimisation of anticoagulation management for patients taking either a DOAC or warfarin.
Topics addressed will be:
- Assessing the appropriate anticoagulation option for a patient – stay on warfarin or switch to a DOAC?
- How to switch from warfarin to a DAOC
- Identifying AF on ECG
- Use of remote ECG technology
- Infection related AF: does it matter?
- Orbit score for assessing bleeding risk
- Assessing warfarin control
- Rate vs rhythm control
- Who needs an echo and who needs to see a cardiologist?
- Appropriate dosing of the DOACs
- What to do with a DOAC pre-op
- Patients with AF and coronary disease – antiplatelet or not?
- Anticoagulation options in VTE
Your expert
GPwSI Cardiology and Cardiovascular Lead, Northamptonshire CCG.
Added bonus for every session…
Quick to complete CPD
Downloadable factsheet
Part 2 – Optimising anticoagulation outcomes: Right medicine, right patient, right time, right dose, right route
Click here for the Eliquis (apixaban) prescribing information.
Part 2 has been organised and funded by BMS-Pfizer and is intended for UK Healthcare Professionals only.
GPwSI Cardiology and Cardiovascular Lead, Northamptonshire CCG.
This session is intended for primary care physicians in the UK who manage patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE).
During this promotional session, our expert speaker will present considerations for optimising anticoagulation outcomes in patients with NVAF or VTE. The session will include discussion around:
- Latest guidance for use of anticoagulation therapy in NVAF and VTE, as well as shared care principles
- Key recommendations and discussion points for counselling patients
- Optimising anticoagulation outcomes in different clinical scenarios
ELIQUIS® (apixaban) is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or TIA, age ≥75 years, hypertension, diabetes mellitus or symptomatic heart failure (NYHA Class ≥II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.1
- ELIQUIS (apixaban) Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/search/?q=eliquis&dt=1.
432-GB-2200096 | May 2022
If you cannot attend the live broadcasts, the webinars will be available on-demand after the event.
